PAR:ALCLS

Cellectis S.A. Stock Insider Trading

Euronext Paris > Healthcare > Biotechnology

1.67€

-0.0500 (-2.91%)

At Close: Jun 26, 2024

Cellectis S.A. Stock Insider Power

Based on the 0 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 0 ALCLS.PA shares in the last 0 trades.

Historical Insider Trades

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

Sorry! Image not available at this moment

About Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... ALCLS.PA Profile

Golden Star

Ticker	Date	Change	Price
EVBG	Jun 21	0.0863%	$34.76
DDOG	Jun 21	1.33%	$117.57
BRK-A	Jun 20	0.575%	$617,249.90
EPD	Jun 18	2.90%	$28.30
USFD	Jun 18	4.33%	$53.14
INTC	Jun 18	0.359%	$30.63
UFPT	Jun 18	2.05%	$253.79
^DJI	Jun 18	0.714%	38,834.86 points
RGA	Jun 17	1.53%	$203.90
MA	Jun 17	1.68%	$448.11

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Sign In